PROCEPT BIOROBOTICS CORPORATION - COMMON STOCK

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

13 May 2024 16:05:00 By Nasdaq GlobeNewswire

Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

29 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

23 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

04 Apr 2024 16:04:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

02 Apr 2024 16:03:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

27 Feb 2024 16:02:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

12 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million

08 Jan 2024 17:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City

13 Nov 2023 16:03:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

01 Nov 2023 16:02:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

16 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation

12 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose

20 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer

12 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

22 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

17 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

NorthShore University HealthSystem offers expanded access to treat most common prostate ailment

16 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

01 Aug 2023 22:10:39 By Nasdaq GlobeNewswire